"Targeted ANGPTL3 inactivation in nonhuman primates was well-tolerated and led to a > 90% mean reduction in circulating ANGPTL3 protein, with durability confirmed out to 3 years following a single dose." nature.com/articles/s4158…
www.nature.com In Vivo CRISPR Base Editing of ANGPTL3 for Durable Lipid Lowering Nature - In Vivo CRISPR Base Editing of ANGPTL3 for Durable Lipid Lowering Chris Mason
Verified account This account is verified. Learn more@mason_lab
Professor of Genomics, Physiology, & Biophysics @WeillCornell Medicine. Co-Founder / COI @BiotiaNYC, @UrsaBio & @Onegevity (@thornehealth)
983 Following 12K Followers 9.1K Posts
Latest posts 5
"Design is the beauty of turning constraints into advantages" - Aza Raskin
Extraordinary power of iPSCs: "Voices: What impact has iPSC technology had on your research and/or field?"
cell.com/stem-cell-repo…
cell.com/stem-cell-repo…
"Modulator Resolves Transcript-, Allele-, and Condition-associated RNA Modification Differences from Direct RNA Sequencing." biorxiv.org/content/10.648… our lab's cool new algorithm and epitranscritpome analysis tool set led by Theo @MakeBrainHappy in partnership with the Horner lab. Check it out!
"Clinical actionability of metagenomic next-generation sequencing for antimicrobial stewardship for urinary tract infections: a retrospective, single-centre, BI-Biotia UTI cohort study" new paper with @BiotiaInc ijidonline.com/article/S1201-…